Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,051 across all filing types
Latest filing 2019-05-14 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 100% confidence The document text is extremely short (62 characters) and contains no substantive content, only a placeholder for a picture. There is no financial data, no report content, no announcements, or any other information to classify as a specific report type. Given the lack of content, the document does not fit any specific filing category and defaults to the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2019-05-14 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for a specific drug product. It is addressed to stock exchanges and includes a media release. The content is an announcement of a regulatory approval event, not a financial report, management discussion, or any other detailed filing. The document length is under 5,000 characters and it is clearly a press release or announcement rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-05-14 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the results of a Phase 3 clinical study for a pharmaceutical product (Ryaltris) by Glenmark Pharmaceuticals. It is addressed to stock exchanges and includes a media release with detailed study results, safety data, and company information. There is no indication that this is a financial report, regulatory filing, or management discussion. It is a corporate announcement related to clinical trial results, which does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The document is not a report publication announcement since it contains substantive information rather than just announcing a report's availability. The closest fitting category is Regulatory Filings (RNS) as a general regulatory announcement or corporate news that does not fit other specific categories.
2019-05-09 English
Press Release
Board/Management Information Classification · 95% confidence The document is a press release dated May 7, 2019, announcing the appointment of Dr. Yasir Rawjee as CEO of Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals. It is addressed to stock exchanges and includes a media release. The content focuses on management appointment and company business strategy related to the API business. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The document is not a report but an announcement of a management change. Therefore, it fits the category of Board/Management Information (MANG). The document length is about 5,127 characters, which is consistent with a detailed announcement rather than a full report.
2019-05-07 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release dated May 3, 2019, announcing a co-promotion agreement between Glenmark Therapeutics and Otonomy for a pharmaceutical product (OTIPRIO) in the U.S. It is addressed to stock exchanges and includes detailed information about the agreement, the product, and company background. There are no financial statements, regulatory filings, or report attachments. The content is a corporate announcement about a business development related to product promotion and partnership, not a financial report, earnings release, or regulatory filing. Therefore, the document best fits the category of a Capital/Financing Update (CAP) as it relates to a strategic commercial agreement impacting the company's business operations and portfolio expansion.
2019-05-03 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new pharmaceutical product, Remogliflozin, by Glenmark Pharmaceuticals. It contains no financial data, regulatory filings, or detailed financial reports. It is a corporate announcement about a product launch, not a financial report, earnings release, or regulatory filing. The document is not a report itself but a media release intended for public and investor information. Therefore, it fits best under the category of a Regulatory Filing (RNS) as a general corporate announcement that does not fit other specific categories.
2019-04-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.